[go: up one dir, main page]

MX2018000800A - Formulaciones y tratamientos topicos. - Google Patents

Formulaciones y tratamientos topicos.

Info

Publication number
MX2018000800A
MX2018000800A MX2018000800A MX2018000800A MX2018000800A MX 2018000800 A MX2018000800 A MX 2018000800A MX 2018000800 A MX2018000800 A MX 2018000800A MX 2018000800 A MX2018000800 A MX 2018000800A MX 2018000800 A MX2018000800 A MX 2018000800A
Authority
MX
Mexico
Prior art keywords
weight
parts
formulations
pharmaceutical formulation
topical treatments
Prior art date
Application number
MX2018000800A
Other languages
English (en)
Other versions
MX390004B (es
Inventor
H Alur Hemant
A H Harwick James
Original Assignee
Trilogic Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trilogic Pharma Llc filed Critical Trilogic Pharma Llc
Publication of MX2018000800A publication Critical patent/MX2018000800A/es
Publication of MX390004B publication Critical patent/MX390004B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una formulación farmacéutica y un método asociado con la misma para tratar viginosis bacteriana. La formulación farmacéutica incluye de 10 a 25 partes en peso de poloxámero F127, de 0.5 a 3.0 partes en peso de goma de xantano, de 70 a 90 partes en peso de agua, y una cantidad terapéuticamente efectiva de un ingrediente activo farmacéutico. La formulación farmacéuticamente también puede incluir de 0.5 a 1.5 partes en peso de alcohol bencílico.
MX2018000800A 2015-07-20 2016-07-18 Formulaciones y tratamientos topicos. MX390004B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562194518P 2015-07-20 2015-07-20
PCT/US2016/042843 WO2017015232A1 (en) 2015-07-20 2016-07-18 Topical formulations and treatments

Publications (2)

Publication Number Publication Date
MX2018000800A true MX2018000800A (es) 2018-08-16
MX390004B MX390004B (es) 2025-03-04

Family

ID=57835134

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000800A MX390004B (es) 2015-07-20 2016-07-18 Formulaciones y tratamientos topicos.
MX2022001736A MX2022001736A (es) 2015-07-20 2018-01-18 Formulaciones y tratamientos topicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001736A MX2022001736A (es) 2015-07-20 2018-01-18 Formulaciones y tratamientos topicos.

Country Status (11)

Country Link
US (3) US11129896B2 (es)
EP (1) EP3324938B1 (es)
CA (2) CA3209380A1 (es)
DK (1) DK3324938T3 (es)
ES (1) ES2891754T3 (es)
HU (1) HUE056401T2 (es)
LT (1) LT3324938T (es)
MX (2) MX390004B (es)
PL (1) PL3324938T3 (es)
PT (1) PT3324938T (es)
WO (1) WO2017015232A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2891754T3 (es) 2015-07-20 2022-01-31 Trilogic Pharma Llc Formulaciones y tratamientos tópicos
BR112018015143A2 (en) 2016-02-09 2018-12-18 Bracco Suisse Sa recombinant chimeric protein for selectin targeting
EP4376890A2 (en) * 2021-07-26 2024-06-05 Daré Bioscience, Inc. Compositions for use in the treatment of dysmenorrhea
AU2022318739A1 (en) * 2021-07-26 2024-02-15 Daré Bioscience, Inc. Compositions for use in the treatment of bacterial vaginosis
WO2024155777A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024155775A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024158951A2 (en) * 2023-01-25 2024-08-02 Dare Bioscience, Inc. Compositions and methods for treating dysmenorrhea

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218023B1 (en) 1997-04-21 2001-04-17 Montell North America, Inc. Co-extruded laminate comprising at least one propylene graft copolymer layer
CN1120000C (zh) * 1997-11-24 2003-09-03 曾忠铭 刺激阴道革兰氏阳性杆菌生长、增强阴道酸度的药剂和其用途
US20040167223A1 (en) 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
CN1311873C (zh) * 2004-06-30 2007-04-25 上海复康医药科技发展有限公司 一种温度敏感的阴道用原位凝胶制剂
EP2219608B1 (en) 2007-12-03 2014-03-19 Trilogic Pharma Llc Self solidifying bioerodible barrier implant
CA2712120A1 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
CN102525884A (zh) * 2010-12-19 2012-07-04 复旦大学 一种用于阴道给药的温敏原位凝胶制剂
JP6210985B2 (ja) 2011-08-31 2017-10-11 ベリー プラスチックス コーポレイション 断熱容器用のポリマー材料
AR093151A1 (es) 2012-10-26 2015-05-20 Berry Plastics Corp Material polimerico para aislacion de recipientes
ES2891754T3 (es) 2015-07-20 2022-01-31 Trilogic Pharma Llc Formulaciones y tratamientos tópicos

Also Published As

Publication number Publication date
EP3324938A4 (en) 2019-03-13
US20220040306A1 (en) 2022-02-10
HUE056401T2 (hu) 2022-02-28
WO2017015232A1 (en) 2017-01-26
LT3324938T (lt) 2021-11-25
US20250249105A1 (en) 2025-08-07
PT3324938T (pt) 2021-09-21
CA2993012C (en) 2023-10-03
CA3209380A1 (en) 2017-01-26
MX390004B (es) 2025-03-04
ES2891754T3 (es) 2022-01-31
EP3324938A1 (en) 2018-05-30
DK3324938T3 (da) 2021-09-27
PL3324938T3 (pl) 2022-01-10
MX2022001736A (es) 2022-03-11
CA2993012A1 (en) 2017-01-26
US20180207275A1 (en) 2018-07-26
US12303563B2 (en) 2025-05-20
EP3324938B1 (en) 2021-09-01
US11129896B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
MX2018000800A (es) Formulaciones y tratamientos topicos.
AR133768A2 (es) Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
CL2020000747A1 (es) Formulaciones de niraparib.
MX2020003250A (es) Composiciones sinegísticas de pesticidas y métodos para la entrega de ingredientes activos.
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MX387604B (es) Formulaciones cannabinoides estables.
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
GT201700280A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CO2020002624A2 (es) Formulación de uso tópico para el control y la prevención de parásitos en animales
BR112015007592A2 (pt) composições de enalapril
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
MX384159B (es) Formulaciones y métodos para el suministro vaginal de antiprogestinas.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
CR20160021A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX376014B (es) Composicion para el cuidado bucal.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EP2842938A4 (en) NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY SALTS AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE AGENT
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
CL2017002258A1 (es) Formulación cosmética antioxidante para uso tópico que comprende una asociación de extractos de plantas y uso de la misma